Lipid News

Acylcarnitines, a warning signal for Type 2 diabetes

Jessica W. Davidson Judith Simcox
By Jessica W. Davidson and Judith Simcox
March 15, 2022

Type 2 diabetes, or T2D, is a chronic disease characterized by insulin resistance that impacts 34.2 million people in the United States. Another 88 million adults are prediabetic, meaning they likely will develop diabetes if they do not receive preventative care. Risk factors for T2D include aging, genetics and obesity. An estimated 89% of adults diagnosed with T2D between 2013 and 2016 were obese.

Acylcarnitines can be measured in blood plasma using mass spectrometry and are associated with insulin resistance, which can serve as a warning sign for development of Type 2 diabetes.
Acylcarnitines can be measured in blood plasma using mass spectrometry and are associated with insulin resistance, which can serve as a warning sign for development of Type 2 diabetes. With stress such as exercise and cold exposure, insulin signaling helps with rapid fuel switching, making acylcarnitines beneficial in these states.

Irregular lipid metabolism associated with obesity and T2D is termed diabetic dyslipidemia, which includes increased plasma triglycerides and low-density lipoprotein cholesterol. This dyslipidemia occurs in 70% of T2D cases and is associated with higher rates of secondary conditions such as cardiovascular disease. Using mass spectrometry, researchers have found that dyslipidemia is associated with increases in more than 300 lipid species in the plasma, and there is mounting evidence that lipids contribute to T2D as signaling molecules.

Acylcarnitines, one of the lipid classes elevated in plasma with diabetic dyslipidemia, function in transport and signaling. In cells, acylcarnitines are made when a fatty acid is bound to carnitine on the outer mitochondria membrane by the enzyme carnitine palmitoyltransferase 1, or CPT1. Then acylcarnitines are transported into the mitochondria matrix, where they are converted back to free carnitines and fatty acid to be broken down by beta-oxidation for energy production. Acylcarnitines also can evade mitochondrial entry and are exported to the blood plasma.

Plasma acylcarnitines contribute to insulin resistance in obesity and T2D. Mice with genetic loss of CPT1 have lower plasma acylcarnitines and greater insulin sensitivity, while mice with a more active form of CPT1 have higher levels of acylcarnitines and insulin resistance. When Mary-Ellen Harper’s lab at the University of Ottawa treated isolated skeletal muscle cells with acylcarnitines, insulin resistance rapidly developed.

So, why would acylcarnitines signal for insulin resistance?

Plasma acylcarnitines increase in diabetes but also with normal stress such as exercise and cold exposure. Deborah Muoio’s lab at Duke University showed that loss of acylcarnitine processing in muscles leads to exercise intolerance, and work from our lab established that mice with a loss of CPT1 are intolerant to cold. A variant of CPT1 is abundant in Inuit populations of Greenland, Alaska and Canada. Work from our laboratory at the University of Wisconsin–Madison describes how this CPT1 variant is constitutively active, leading to higher acylcarnitine levels, which would be beneficial in response to the cold environment inhabited by the Inuit.

Exertion and cold cause organisms to switch fuel sources rapidly from glucose to lipids. Since insulin stimulates glucose uptake, insulin resistance might be advantageous for the switch to lipids. Acylcarnitine signaling could potentiate insulin resistance to facilitate the fuel transition, but the question is how.

As prediabetes and diabetes prevalence increases, we must identify early warning signs and understand the underlying pathobiology. Acylcarnitines are a piece of the puzzle; questions still loom about their transport and regulation in T2D. Understanding how acylcarnitines signal for insulin resistance and their functional role in normal physiology such as cold stress can hold the key to therapeutic intervention for T2D.

Want more lipid research news?

Check out Lipid Trends, a curated collection of hot picks from the world of lipid research, brought to you by LIPID MAPS.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Jessica W. Davidson
Jessica W. Davidson

Jessica W. Davidson is a graduate researcher in Judith Simcox’s laboratory in the Integrative Program in Biochemistry at the University of Wisconsin–Madison.

Judith Simcox
Judith Simcox

Judith Simcox is an assistant professor in the biochemistry department at the University of Wisconsin–Madison.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Guiding grocery carts to shape healthy habits
Award

Guiding grocery carts to shape healthy habits

Nov. 21, 2024

Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

Quantifying how proteins in microbe and host interact
Journal News

Quantifying how proteins in microbe and host interact

Nov. 20, 2024

“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.

Leading the charge for gender equity
Award

Leading the charge for gender equity

Nov. 19, 2024

Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.

CRISPR gene editing: Moving closer to home
News

CRISPR gene editing: Moving closer to home

Nov. 17, 2024

With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.

Finding a missing piece for neurodegenerative disease research
News

Finding a missing piece for neurodegenerative disease research

Nov. 16, 2024

Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.

From the journals: JLR
Journal News

From the journals: JLR

Nov. 15, 2024

Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.